Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Bone Marrow Transplant ; 50(12): 1563-71, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26367225

ABSTRACT

Graft versus host disease (GVHD) is a major complication of haematopoietic SCT (HSCT). A number of inflammatory cytokines/chemokines are implicated in GVHD and have been identified in numerous single centre studies as potential biomarkers for acute and/or chronic GVHD. In this study, we analysed candidate inflammatory biomarkers (B-cell activating factor (BAFF), interleukin 33 (IL-33), CXCL10 and CXCL11) in a two-centre study. Biomarkers were evaluated pre-transplant and at serial time points post transplant in acute and chronic GVHD patient sera with time-matched control samples from patients without GVHD. Further validation was performed using the human skin explant assay, clinical GVHD biopsies and mRNA expression analysis. BAFF was significantly increased pre-transplant. BAFF, IL-33, CXCL10 and CXCL11 showed increased levels in acute GVHD patient sera and high protein expression in grades II-III of the in vitro skin explant graft versus host reaction (GVHR) group. BAFF, CXCL10 and CXCL11 also showed increased mRNA expression levels in clinical biopsies compared with the no/low-grade GVHD group. BAFF, CXCL10 and CXCL11 levels were increased in chronic GVHD patient sera. The results identify BAFF and CXCL10 as predictive biomarkers for acute GVHD and BAFF, CXCL10 and CXCL11 as useful diagnostic biomarkers for acute GVHD and chronic GVHD.


Subject(s)
Graft vs Host Disease/blood , Graft vs Host Disease/diagnosis , Hematopoietic Stem Cell Transplantation , Acute Disease , Allografts , Biomarkers/blood , Chronic Disease , Cytokines , Female , Graft vs Host Disease/etiology , Hematologic Neoplasms/blood , Hematologic Neoplasms/therapy , Humans , Male
3.
J Laryngol Otol ; 123(2): 223-8, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18485252

ABSTRACT

AIM: To evaluate the efficacy of pure natural honey as prophylaxis against radiochemotherapy-induced mucositis, through clinical scoring of oral and oropharyngeal mucositis, and culturing of pathogenic oral and oropharyngeal microbes. PATIENTS AND METHODS: The study was done in Assiut University Hospital, Egypt, between January 2005 and July 2006. Forty patients diagnosed with head and neck cancer were entered into the trial. Enrolled patients were randomised to either the treatment group, receiving concomitant chemotherapy and radiotherapy (with a significant area of directly visible oral and/or oropharyngeal mucosa included in the radiation fields) plus prior topical application of pure natural honey, or the control group, receiving concomitant chemotherapy and radiotherapy without honey. Patients were evaluated clinically every week to assess development of radiation mucositis. Aerobic cultures and candida colonisation assessment were undertaken, via oral and oropharyngeal swabs, prior to and at the completion of irradiation, and when infection was evident. RESULTS: In the treatment group, no patients developed grade four mucositis and only three patients (15 per cent) developed grade three mucositis. In the control group, 13 patients (65 per cent) developed grade three or four mucositis (p < 0.05). Candida colonisation was found in 15 per cent of the treatment group and 60 per cent of the control group, either during or after radiotherapy (p = 0.003). Positive cultures for aerobic pathogenic bacteria were observed in 15 per cent of the treatment group and 65 per cent of the control group, during or after radiotherapy (p = 0.007). CONCLUSION: This study shows that prophylactic use of pure natural honey was effective in reducing mucositis resulting from radiochemotherapy in patients with head and neck cancer.


Subject(s)
Anti-Infective Agents, Local/administration & dosage , Head and Neck Neoplasms/radiotherapy , Honey , Mouth Mucosa/radiation effects , Mucositis/therapy , Radiation Injuries/therapy , Administration, Topical , Combined Modality Therapy/adverse effects , Female , Head and Neck Neoplasms/drug therapy , Humans , Male , Middle Aged , Mucositis/microbiology , Radiation Injuries/microbiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...